Latest / Sunny Mornings Boston
Eli Lilly's $7B Boston Biotech Buy, Bruins Seek Redemption
Tuesday April 21, 2026
In this episode, we delve into Eli Lilly's strategic acquisition of Boston-based biotech firm Kelonia Therapeutics for $7 billion, marking a significant expansion in Massachusetts' thriving biotech sector. This deal highlights the potential of Kelonia's innovative cell therapies for blood cancers, including a promising treatment for multiple myeloma. Meanwhile, Boston's sports scene is buzzing with the Bruins seeking redemption against the Buffalo Sabres in the first round of the playoffs after a surprising comeback loss. On the baseball diamond, the Red Sox evened…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.